The group, including co-hosts Louise Campbell and Roger Green along with guests Jeff McIntyre and Mike Betel, dives deeper into the care challenges and barriers confronting MASH patient care today.
Global Liver Institute Vice President of Liver Programs Jeff McIntyre describes the rational behind GLI’s 2024 theme, after which Mike Betel and Roger Green share reactions.
Patient advocates Jeff McIntyre (Global Liver Institute) and Mike Betel (Fatty Liver Alliance, Liver Action Network) join Louise Campbell and Roger Green to discuss GLI’s premier MASH patient event, now known as Global Fatty Livery Day.
Fatty Liver Alliance Founder Mike Betel joins Roger Green to consider how patient incentives to participate in MASH clinical trials might need to change now that prescribers have an approved drug for treating MASH patients.
MASLD patient advocates consider new needs and opportunities for other stakeholders after the Rezdiffra approval and launch.
MASLD patient advocates consider the impact Rezdiffra approval and accompanying promotion and education might have on the U.S. healthcare system.
This conversation focuses on how the role of MASLD patient advocates might change and expand in the aftermath of Rezdiffra being approved. MAFLD patient advocates consider how their roles might change and expand now that Rezdiffra has been approved.
Five leading MASLD patient advocates discuss their initial reactions when Rezdiffra became the first MASH drug approved in the US on March 14.
Leading patient advocates help the Surfers identify the target MASH patients for Rezdiffra and discuss Madrigal’s extensive patient support program.
The conversation on Rezdiffra, the first MASH drug, wraps up with the panelists answering a inviation to discuss any other issues of interest that had not arisen in the conversation.
